Almost $14 million spent advertising Invokana in medical journals through Q3 2014
Through September 2014, Invokana continues to be the drug product most advertised in medical journals. Invokana, which treats type 2 Diabetes, has spent the most in advertising and purchased the highest number of ad pages, according to Kantar Media. Brintellix, an antidepressant, ranks second by both dollars and pages. Xarelto, which ranked first at this time in 2013, now ranks third.
Top 5 Print Ad Drugs (Dollars): September 2014
- Invokana – $14 MM (+31%)
- Brintellix Tablets – $9 MM (N/A)
- Xarelto - $5 MM (-54%)
- Belviq (Lorcaserin HCI) IV - $5 MM (+378%)
- Fetzima – $5 MM (N/A)
The percentage changes compare September 2014 to that same time period in 2013. For more information on these ad insights or other data, let one of us know.
Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in the professional healthcare arena. Check back next month for updated data on the top products, classes, companies and category movers year-to-date.